News & Updates
Showing Oncology articles
Showing
Transplant-ineligible myeloma: Daratumumab added to VCD deepens haematological response, improves PFS
Addition of daratumumab to the bortezomib, cyclophosphamide, and dexamethasone (VCD) regimen provides deeper haematological responses and improves progression-free survival (PFS) in patients with newly diagnosed myeloma who are not eligible for autologous stem cell transplantation (ASCT), according to the results of the AMaRC 03-16 phase II study.
Chemo plus atezolizumab improves survival while preserving life quality in advanced EC
Treatment with carboplatin-paclitaxel (CP) plus atezolizumab results in better quality-adjusted survival in patients with advanced or recurrent endometrial cancer (EC) as compared with CP alone, according to a post hoc analysis of the AtTEnd/ENGOT-EN7 trial.
Navitoclax–ruxolitinib combo doubles spleen response rates in myelofibrosis
In untreated myelofibrosis, using navitoclax in combination with ruxolitinib appears to result in a twofold increase in the number of patients experiencing spleen volume shrinkage, regardless of prognosis, according to updated data from the phase III TRANSFORM-1 trial.
AI improves physician accuracy in identifying prostate cancer extent
Use of artificial intelligence (AI)-assisted cancer contours helps minimize underestimation of the extent of prostate cancer, thereby improving the physician’s ability in terms of contouring accuracy and negative margin rate, a study has shown.
